Welcome
Support Centre
12 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ ...Back to search results ] [ Print-friendly version ]
The Efficacy of Acupuncture in Stroke Recovery
ISRCTN ISRCTN29932220
ClinicalTrials.gov identifier
Public title The Efficacy of Acupuncture in Stroke Recovery
Scientific title The effect of acupuncture versus standard Western therapy in reducing the rate of deformity of stroke and in improving the quality of life in adult patients: a multicentre randomised controlled trial
Acronym EASR
Serial number at source D08050703550902
Study hypothesis Under the guidance of the theory of Chinese medicine, acupuncture is widely used in treating the stroke in China for a long time. This study is to evaluate the effect of acupuncture in reducing the rate of deformity of stroke and in improving the quality of life.
Lay summary
Ethics approval Research Ethical Committee of the Beijing Hospital of Traditional Chinese Medicine approved on the 22nd January 2010 (ref: 201002-1)
Study design Multicentre randomised controlled study
Countries of recruitment China
Disease/condition/study domain Stroke
Participants - inclusion criteria 1. Stroke Patients were diagnosed according to criteria of cerebral arterial thrombosis in Western medicine and the criteria of apoplexy in Chinese medicine
2. The stroke patients were hospitalised because of the acute cerebral arterial thrombosis, that occurred in 10 days
3. Male or female, aged 40 - 75 years
4. National Institutes of Health Stroke Scale (NIHSS) grade from 4 to 21
5. Glasgox Coma Score greater than or equal to 7
6. Patients on the first attack or with a cerebral stroke history but with on serious deformity, modified Rankin Scale (mRS) grade less than or equal to 1
7. Patients who took part in the trail voluntarily and signed the informed consent form
Participants - exclusion criteria 1. Patients under the treatment of thrombolysis
2. Patients under other clinical trials, or having undergone other clinical trials in the last 3 months
3. Patients with severe primary diseases in cardiovascular system, liver, kidney, hematopoietic system, and psychopathy
4. Pregnant women or women in breast feeding period
5. Inborn handicaps
Anticipated start date 01/09/2009
Anticipated end date 30/06/2012
Status of trial Ongoing
Patient information material Not available in web format, please contact shizheng83@hotmail.com to request a patient information sheet
Target number of participants 328
Interventions A total of 328 patients on the acute stage of cerebral apoplexy will be recruited. The patients were randomly divided into two different groups: the intervention group received the treatment of acupuncture and the Western Medicine standard treatment for 3 months and the secondary prevention treatment for 6 months, and the control group received the standard therapy of the Western medicine for 3 months and the secondary prevention treatment for 6 months. Both groups were evaluated with the treatment course of 4 weeks, 12 weeks and 24 weeks.

Group A (intervention group):
Patients are stimulated by 7 main acupoints: Baihui (Du-20), Quchi (LI-11), Shousanli (LI-10), Hegu (LI-4), Zusanli (ST-36), Yanglingquan (GB-34), Sanyinjiao (SP-6). Acupoints association is used under the guidance of the theory of Chinese medicine and according to the patients' different symptoms, the acupoints below are commonly used: Jianyu (LI-15), Huantiao (GB-10), Qiuxu (GB40), twelve well-jing points, Jinjin (EX-HN 12), Yuye (EX-HN 13), Yamen (DU-15), Lianquan (RN 23), Tianshu (ST-25), Fenglong (ST-40), limb spasm assists with fire needles.

The acupoints are stimulated by the filiform needles and the needles are remained for 30 minutes. Patients on the acute stage are treated with the acupoints of Baihui (Du-20), Jinjin (EX-HN 12), Yuye (EX-HN 13), Sishencong (EX-HN 1) and the twelve well-jing points, that use quick insertion of the tri-ensiform needles for bleeding. The needles are remained for 30 minutes every other day, three times a week.

As well as the western medicine standard therapy for 3 months and the secondary prevention treatment (the blood pressure control, platelet aggregation, glucose control, etc) for 6 months.

Group B:
Received the treatment of the standard therapy - the intracranial pressure (ICP) control, the blood pressure control, platelet aggregation, routine physiotherapy and occupational therapy, the secondary prevention treatment as well.

Joint Sponsor:
Beijing Hospital of Traditional Chinese Medicine (China)
No. 23 Meishuguanhoujie
Dongcheng District
Beijing 100010
China
T: +86 (0)10 5217 6852
F: +86 (0)10 5217 6808
Email: postmaster@bjzhongyi.com
Website: http://www.bjzhongyi.com
Primary outcome measure(s) 1. Barthel Index (BI)
2. Stroke-Specific Quality Of Life (SS-QOL)

Assessments will be conducted at the baseline and at week 4, 12 and 24 follow-up.
Secondary outcome measure(s) 1. The National Institutes of Health Stroke Scale (NIHSS)
2. Modified Rankin Scale (mRS)

Assessments will be conducted at the baseline and at week 4, 12 and 24 follow-up.
Sources of funding 1. Beijing Municipal Science and Technology Commission (China)
2. Beijing Hospital of Traditional Chinese Medicine (China)
Trial website
Publications
Contact name Prof  Lingpeng  Wang
  Address Beijing Hospital of Traditional Chinese Medicine
No.23 Meishuguanhoujie
Dongcheng Dis.
  City/town Beijing
  Zip/Postcode 100010
  Country China
  Tel +86 (0)10 5217 6636
  Fax +86 (0)10 5217 6808
  Email wlp5558@sina.com
Sponsor Beijing Municipal Science and Technology Commission (China)
  Address No. 16 Xizhimendajie
Xicheng Dis.
  City/town Beijing
  Zip/Postcode 100035
  Country China
  Tel +86 (0)10 6615 3395
  Email bjkwwz@sina.com
  Sponsor website: http://www.bjkw.gov.cn/n1143/index.html
Date applied 11/04/2010
Last edited 07/05/2010
Date ISRCTN assigned 29/04/2010
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central